Diumal Variation in the Response to ACTH by Janet Sadow1 BSC MB and Susan Knight BSC (Royal Free Hospital School ofMedicine, London) and W J Irvine DSC FRCPEd (Royal Infirmary, Edinburgh) In 1970, Retienne made the observation that it is possible to modify the action of a hormone by altering not only the dosage but also the time of day at which it is administered.
ACTH'-'8 in a dose of 0.5 ,ug/100 g body weight was administered subcutaneously to groups of rats, and the time course of the resultant corticosterone in the blood was determined by fluorimetry. This procedure was followed at 1200 on some days and at 1600 on others. It was found that the corticosterone in the blood remained elevated at higher levels for longer when ACTH1-18 was given at 1200, than if given in the same dose by the same route at 1600 (Fig 1) . However, the initial levels of corticosterone attained were the same after both injection times.
In order to investigate this phenomenon further, the diurnal cycle in blood levels of corticosterone in one particular strain of rat under natural lighting conditions was verified (Guillemin et al. 1959 , Hodges & Mitchley 1970 . The rat shows almost the reverse of the human rhythm, i.e. the trough of the rat cycle occurs at 0800 to 1200. Thereafter follows a steep rise to a peak at 1600 and possibly two further peaks on the plateau through the early part of the night, falling again by 0400.
The biodynamics consequent upon a single injection of ACTH are complex. Exogenous ACTH causes a raised blood level of ACTH which may or may not decay at different speeds dependent on a diurnal rhythm. ACTH acts upon the adrenal cortical enzymes which are reported to have a diurnal response (Ungar & Halberg 1962) . The resultant output of corticosterone, measured as total corticosterone both bound and free, partly depends on available binding which could possibly have a diurnal variation. Further, the removal of corticosterone by the liver may have a diurnal component although there is evidence to suggest that the half-life of corticosterone is not significantly altered at the peak compared with the trough (Gibbs 1970) .
The variation in response to ACTH1-24 and ACTH'-18 was investigated. It is possible to demonstrate a similar but less marked phenomenon, despite the more rapid removal of this short-acting peptide.
In an attempt to determine the cause or causes of the alternation in the response to ACTH, exogenous corticosterone was given to groups of 6 rats in a subcutaneous dose of 1 mg/l00g at 1600 (--). Each point represents at least 6 rats. The difference between plasma corticosterone levels at 2 hours after injection is significant atP<0.005 1200 and at 1600 as an approximate match of the ACTH-invoked corticosterone. It was seen that the half-life of corticosterone was not altered by the time of day. However, the single injection given at 1200 did not completely return to the basal control level whereas the injection given at 1600 did so. Without direct estimates of ACTH it is not possible to determine whether there is a diurnal variation in the removal of ACTH. Concerning the hormone's action, there is evidence to suggest that the rat adrenal cortex incubated in vitro is less sensitive to ACTH in the morning than in the afternoon (Ungar & Halberg 1962) and is therefore not responsible for the prolonged levels of corticosterone in the morning samples. The available binding capacity of the blood may be part of the answer and may be the reason for the elevation, when the exogenous corticosterone did not return to the basal levels after the 1200 injection. Removal of corticosterone by the liver is probably eliminated from the list of possible causes, by virtue of its similar half-life at different times in the cycle (Gibbs 1970) .
The main practical significance of this observation is that if a given dose of a hormone has prolonged activity in the blood when given at different times in the diurnal cycle and if that same hormone has side-effects after prolonged treatment over a period of time, it might be important to give the hormone at the time in the cycle when its action is least prolonged, i.e. in man at 0800 and in the rat 1600-2000. This report describes the treatment of six patients with Cushing's disease of hypothalamic-pituitary origin, in whom the diagnosis was established by routine criteria. The patients were treated with one or other of the adrenocortical enzyme inhibitors, metyrapone and aminoglutethimide (Hughes & Burley 1970) , to render them clinically and biochemically euadrenal. At the same time megavoltage therapy (4-6 million volts) was given to the pituitary in a mean dose of 4600 rad over 31 days. The field arrangement was: 1 vertex and 2 lateral with each field measuring 4 x 4 cm.
Six patients, four women and two men aged from 30 to 48 years, were followed for a mean time of 17.5 months (4.5-26). Treatment was monitored by measurement of urinary free 11hydroxycorticosteroids (Mattingly 1962 ) ('cortisol'), plasma ACTH and plasma 11-hydroxycorticosteroids ('cortisol').
Biochemical control, in the form of low normal urinary free cortisol measurements, could be achieved within two weeks, and this was associated with subsequent remission of the clinical features of hyperadrenalism.
The effect of treatment on biochemical measurements is shown in Table 1 . The patients' clinical status appeared to correlate most closely with the results of the urinary free cortisol. In the first 3 cases treatment with adrenal blocking agents has been withdrawn and a sustained remission has occurred. In the second 3 cases relapse of the Cushing's syndrome occurred after withdrawal of blocking agents and treatment has been reinstituted. In one of the latter 3 cases adrenal blocking agents had only been given for six months which is probably insufficient time for the radiation effects on the pituitary to become manifest. Details of each patient's treatment are shown in Fig 1. Side-effects of treatment included seven minor episodes of hypoadrenalism and three episodes requiring admission to hospital. To obviate the risk of hypoadrenalism, dexamethasone is now given routinely along with adrenal blocking drugs. Severe itching occurred in 3 out of 6 cases given aminoglutethimide and necessitated withdrawal of the drug. One of the three had psoriasis. The doses at which this occurred ranged from 0.75 to 1.5 g/day. The patients who did not itch received identical doses. Severe depression was observed in one patient when he was rendered euadrenal. All patients treated with aminoglutethimide were given L-thyroxine because of the known antithyroid actions of this drug. Since aminoglutethimide also blocks aldosterone biosynthesis it is probably wise to prescribe a small dose of fludrocortisone when this drug is given, though this was not a routine procedure in this investigation.
We have-demonstrated that it is possible to render patients with Cushing's disease euadrenal with adrenal blocking drugs. In view of the hazards of adrenalectomy in patients with Cushing's syndrome, particularly if this is severe, it would seem reasonable to render all patients euadrenal before operation. Adrenal blocking therapy can also be used to maintain the euadrenal state while megavoltage therapy is given to the pituitary to halt the primary disease process. It is possible to induce a sustained remission of the Cushing's disease in some patients by this regime.
